Pharmacokinetic crossover trials on GelShield Extended-Release Metformin gut tolerability, topical Diclofenac patch RCTs for targeted joint relief without GI bleeding, and Phase 3 biologic clearance trials in psoriasis and autoimmune disease. Explore 546 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
A total of 91 participants were randomly assigned to CMM alone (n = 50) or 10-kHz SCS plus CMM (n = 41).
FAE administered over a period of 20 weeks demonstrated a better response than placebo; the difference was statistically significant and clinically meaningful.
Between November 2021 and June 2024, 90 patients were randomly assigned (45 per group).
LDD of 1.2% RSV results in significantly greater clinico-radiographic improvement than 1.2% ATV or placebo gels as adjunct to mechanical periodontal therapy.
Tildrakizumab was efficacious for the treatment of scalp psoriasis with no new safety signals.
BICLA and SRI4 may be discordant in SLE trials.
PES incidence was non-inferior between groups.
Radiotherapy for symptomatic Ledderhose disease is an effective treatment resulting in a significant pain reduction, improvement of QoL scores and bare feet walking abilities, in comparison to sham-radiotherapy.
Upadacitinib 15/30 mg continued to be effective in treating clinical and functional outcomes in patients with RA.
Brodalumab demonstrated sustained efficacy and a consistent safety profile in patients with axSpA over 68 weeks.
Prediabetic vs NGT patients with schizophrenia treated with clozapine or olanzapine had increased serum levels of several proinflammatory cytokines, further substantiating the link between inflammation and T2D.
Once-daily HP 0.01% lotion was associated with significant reductions in disease severity in Hispanic participants with moderate-to-severe psoriasis, with good tolerability and safety over 8 weeks.
Antimicrobial therapy in low risk afebrile neutropenic patients can be stopped early.
For gastrointestinal TEAEs, the incidence was related to infection type with higher incidence in Schistosoma mansoni-infected children.
IXEQ4W was associated with rapid and significant improvements in the signs and symptoms of active r-axSpA in Chinese patients at week 16 that were sustained at week 52, with no new safety signals.
Tanezumab 20 mg met the primary efficacy endpoint at week 8.
Targeting the interleukin-5 receptor with benralizumab or circulating interleukin-5 with mepolizumab are effective OGC-sparing strategies in patients with EGPA.
Our results demonstrate that POA dressing is safe and clinically effective for treating split-thickness skin graft donor site wounds.
Ushaq capsules as adjunctive therapy with diclofenac as rescue medication showed greater pain reduction compared to placebo with a favourable safety profile. Larger, longer-term trials with active comparators are needed to confirm these preliminary findings.
Over 50% of initial nonresponders achieved clinical response with extended risankizumab treatment.
Bupropion had a pain-relieving effect independent of CPM efficiency and sensory phenotype. NNT for 50% pain reduction was higher than reported for first-line treatments, but bupropion treatment may still be an option in patients with insufficient response or intolerable side effects on such treatments.
Cyclosporine did not significantly improve ordinal scale outcomes.
Compared with midazolam, the use of remimazolam in diagnostic upper gastrointestinal endoscopy allows for faster sedation induction and recovery, more rapid discharge, and higher patient satisfaction compared with previous...
These findings further support efficacy analyses from MycarinG to highlight the benefit of rozanolixizumab in patients with gMG and demonstrate the utility of the MGII in evaluating patient-relevant symptoms following treatment.
Tissue-associated remodelling profiles highlight heterogeneity within each disease and common molecular features, revealing clinically relevant subgroups.
Rilzabrutinib was well-tolerated, with similar side effects reported in both groups.
Of these, treatment-related, treatment-emergent side effects occurred in 9.2% and 6.2% in the metronidazole and the vehicle group, respectively, but there were no new safety concerns.
The safety profile was generally consistent with previous studies of RZB in psoriasis.
UP and inflammation were reduced in patients with active RA in Japan in both SAR single-drug treatment and SAR + csDMARDs treatment groups.
Fenofibrate may represent a promising add-on therapy in patients with mild-to-moderate UC by modulating inflammation and improving QoL.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
